Risk factor
Negligible price volatility
Profitability factor
Very strong margins and returns
About
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Xofluza, an influenza virus drug; and Tivicay for HIV treatment. It also develops Symproic for opioid-induced constipation treatment; S-120083 for Inflammatory pain; S-010887 for...
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. Specifically, the stock is 'cheap' on P/E, neutral on EV/EBITDA, underpriced on P/
Target Price
The average target price of 4507.T is 2586 and suggests 17% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to d
Buy
Sell